Design of Enzyme Inhibitors in Drug Discovery
Koyel Kar · 2024
In the research and development of pharmaceuticals, enzyme inhibitors have become potent medicinal agents. Opportunities for controlling biological processes and treating a variety of illnesses exist when individual enzymes implicated in disease-related pathways are targeted. This chapter addresses several approaches and difficulties in creating enzyme inhibitors for medicinal use. The significance of enzyme inhibition as a tactic for controlling enzyme activity and obstructing disease processes has been discussed. The active site of an enzyme can be blocked, cofactor binding can be disrupted, or protein–protein interactions that are essential for enzyme function can be affected by enzyme inhibitors. Based on their mode of action, these inhibitors can be divided into an array of groups, such as reversible and irreversible inhibitors, competitive and noncompetitive inhibitors, and allosteric modulators. The following section of the chapter covers different methods used in the creation and development of enzyme inhibitors. A rational design of inhibitors with increased potency and selectivity is made possible by structure-based drug design, which makes use of the three-dimensional structure of the enzyme and computer-aided drug design tools. Lead compounds that can be further optimized using medicinal chemistry techniques can be found through high-throughput screening of chemical libraries. Additional methods used in the development of enzyme inhibitors include fragment-based drug design, virtual screening, and drug discovery based on natural products. However, there are several difficulties in the design of enzyme inhibitors. To prevent off-target effects and reduce potential toxicity, it is essential to achieve selectivity and specificity. The development of creative tactics, such as combination therapy or the targeting of alternate pathways, is necessary to combat drug resistance, which frequently results from mutations in the target enzyme. When designing and refining enzyme inhibitors, pharmacokinetic factors such as bioavailability, metabolic stability, and drug–drug interactions must also be taken into account. Enzyme inhibitors are therefore potential therapeutic agents in drug development. However, issues including achieving selectivity, combating drug resistance, and improving pharmacokinetic features still need to be resolved. The creation of novel enzyme inhibitors with enhanced efficacy and safety profiles is predicted to be facilitated by ongoing research and technical improvements in the sector, which will ultimately result in the identification of innovative medicines for a variety of disorders.